share_log

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

每日生物科技脈搏:分子合作伙伴因雙重壞消息而暴跌,輝瑞/生物科技尋求新冠肺炎入股兒童,輝瑞投資Zentaris
Benzinga Real-time News ·  2022/04/27 08:46
Here's a roundup of top developments in the biotech space over the last 24 hours.
以下是過去24小時生物技術領域的最新進展綜述。
Stocks In Focus
關注的股票
Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years
輝瑞和BioNTech尋求緊急使用5-11歲兒童新冠肺炎疫苗
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age.
輝瑞(紐約證券交易所股票代碼:PFE)和BioNTech SE納斯達克(美國新浪納斯達克股票代碼:BNTX)已經提交了美國食品和藥物管理局緊急使用授權(EUA)申請,為5至11歲的兒童提供10微克加強劑量的新冠肺炎疫苗。
The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series.
提交的材料包括2/3期臨牀試驗的數據,試驗對象為5至11歲的兒童,他們在輝瑞-生物科技新冠肺炎疫苗10微克兩劑初級系列疫苗第二劑接種約六個月後接受了加強劑量。
Molecular...
分...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論